To the Editor: Shepherd and colleagues (July 14 issue)¹ report that erlotinib prolongs survival in non–small-cell lung cancer, as compared with placebo, after the failure of first-line or second-line chemotherapy. One disturbing aspect of this trial is ...

To the Editor: The report by Toff and colleagues on the United Kingdom Pacing and Cardiovascular Events (UKPACE) trial (July 14 issue),¹ evaluating cardiovascular end points in elderly patients with atrioventricular block, showed that the use of dual-...

To the Editor: According to the established definition of multiple sclerosis,¹ the condition in the patient described by Kleinschmidt-DeMasters and Tyler (July 28 issue)² should not have been diagnosed as multiple sclerosis. Apart from the unusual ...

To the Editor: The case of human herpesvirus 8 (HHV-8) reported by Dagna et al. (July 14 issue)¹ is considered to be distinct from HHV-8–associated multicentric Castleman's disease owing to the absence of typical histologic findings and elevated plasma ...

To the Editor: Cukierman et al., in their Clinical Problem-Solving article (Aug. 4 issue),¹ affirm that “the clinical picture suggests primary Sjögren's syndrome because of the lack of clinical features associated with rheumatoid arthritis or other ...

To the Editor: Celiac disease is caused by aberrant T-cell responses to wheat gluten and the gluten-like proteins in barley and rye.¹ The only cure for the disease is a lifelong gluten-free diet. Although consumption of oats is generally considered safe ...